The Controlled Release Society’s (CRS) Nanomedicine and Nanoscale Delivery Focus Group will host their first webinar in March, given by NCL Director, Scott McNeil. This webinar will highlight the unique challenges of nanomedicine development, including the complex characterization requirements for these formulations and the hurdles of regulatory review. Having characterized more than 400 nanomedicines of all platform types, the NCL has amassed a knowledge base of nano-strategies that progress through the “critical path”… and those that don’t. This talk will share some of the lesson learned for nanomedicines, how to identify critical quality attributes, and will attempt to de-mystify the regulatory requirements for nanomedicines. In addition, the presentation will highlight special considerations for the development and translation of follow-on, or generic, nanomedicines.
Nanomedicine Development: Lessons Learned, Approval Earned
Speaker: Scott E. McNeil, Director, Nanotechnology Characterization Lab
Date: Thursday, March 21, 2019
Time: 10 AM-11 AM EDT
More information on how to register will be available soon.